Study Of The Expression Of TXNIP In Pathological Scar

Studies have shown that post-traumatic skin needs the participation of a variety of cells,cytokines and extracellular matrix in the healing process.After three stages of inflammation,tissue formation and tissue remodelling,the wound will eventually form what is often referred to as scar.Clinically,according to the abnormal hyperplasia of scar,scar is divided into two categories:non-pathological scar and pathological scar,in which pathological scar has a great influence on the aesthetics of the skin,but the mechanism of its formation is still unclear.Thioredoxin-acting protein(TXNIP)is an endogenous Trx inhibitory protein.After binding to Trx active cysteine residues,thioredoxin-acting protein can shorten cell cycle,induce apoptosis and autophagy,induce oxidative stress,regulate mitochondrial function,participate in chronic inflammation,regulate mitochondrial function and regulate glucose and lipid metabolism by inhibiting the antioxidant function of Trx.Currently,the research on TXNIP is mainly focused on glucose metabolism-related diseases,myocardial injury-related diseases,fibrosis-related diseases,Alzheimer’s disease and various cancers.Previous studies have found that chronic inflammation plays a promoting role in the occurrence and development of pathological scar,and in the study of the pathogenesis of many diseases involved in chronic inflammation,TXNIP plays an important role in promoting multiple tissue fibrosis through TXNIP-NLRP3-caspase-1-IL-1β/IL18 pathway.In addition,TXNIP can also participate in angiogenesis by mediating the pathway between vascular endothelial growth factor(VEGF)and vascular endothelial growth factor receptor 2(VEGFR2).In the previous study,our team also verified the high expression of TXNIP in vascular endothelial cells by immunohistochemistry.At the same time,our team examined the expression of TXNIP in pathological scar and normal skin,and found that TXNIP expression was higher in pathological scar than in normal skin.When the samples were classified and divided into groups according to clinical diagnosis and treatment factors,it was found that the expression of TXNIP was higher in female and pathological scar with concomitant symptoms,suggesting that TXNIP may play a positive role in the occurrence and development of pathological scar.On the basis of previous studies,this study detected and compared from the protein level and molecular level,in order to further verify the previous research results,and explore the role of TXNIP in the occurrence and development of pathological scar.Research purposeThe level of TXNIP mRNA was detected by qRT-PCR and the expression level of TXNIP protein was detected by Western blot.The expression of TXNIP in keloid,hypertrophic scar,non-pathological scar and normal skin was studied,and the high expression of TXNIP in pathological scar was verified.It is further confirmed that TXNIP may play a positive role in the occurrence and development of scar.At the same time,the samples were classified and grouped by different research variables to detect the expression of TXNIP,to determine which clinical factors belong to the most relevant factors of TXNIP in the occurrence and development of scar,so as to provide corresponding theoretical support for clinical diagnosis and treatment.Research objectThis study included 59 patients who were treated for superficial scars or emergency trauma in the first affiliated Hospital of Zhengzhou University from February 2021 to December 2021.After signing the informed consent,they were given superficial scar resection or debridement and cosmetic suture.The remaining scar tissue after pathological examination or the residual skin tissue at the time of pruning the wound margin were collected,Among them,20 were keloids,14 were hypertrophic scars,14 were non-pathological scars and 10 were normal skin.According to the different types of scars,all specimens were divided into four groups:keloids group,hypertrophic scars group,non-pathological scars group and normal skin group.Research methods1.QRT-PCR was used to detect the mRNA expression of TXNIP in each group.2.Western blot was used to detect the protein expression of TXNIP in each group.3.The pathological scars was scored by Vancouver scar scale(VSS)to study the correlation between the protein expression of TXNIP and VSS score in pathological scar.4.Collect the clinical related factors of patients with pathological scar(including gender,age,location,concomitant symptoms,treatment history,family history),and understand the correlation between the protein expression of TXNIP and these clinical factors.Result1.Detection of TXNIP mRNA level in each group by qRT-PCR.The average mRNA expression level of TXNIP was found to be 1.01±0.01 in the keloids group,0.95±0.05 in the hypertrophic scars group,0.51±0.02 in the non-pathological scars group and 0.45±0.05 in the normal skin group.The expression level of TXNIP mRNA in keloid group and hypertrophic scars group was significantly higher than that in non-pathological scars group and normal skin group,with statistically significant differences(P<0.05).2.Detection of TXNIP protein expression level in each group by Western blot.The relative expression of TXNIP protein was found to be 2.14±0.65 in the keloids group,1.90±0.65 in the hypertrophic scars group,1.04±0.12 in the non-pathological scars group and 0.98±0.11 in the normal skin group.The expression level of TXNIP protein in keloid group and hypertrophic scars group was significantly higher than that in non-pathological scars group and normal skin group,with statistically significant differences(P<0.05).3.Study on the relationship between the protein expression level of TXNIP and the VSS score of pathological scar.The relative expression of TXNIP protein in the high scoring group of pathological scars was 2.36±0.54,and in the low scoring group of pathological scars was 1.37±0.82.The difference between the two groups was statistically significant(P<0.05).4.Study on the relationship between the expression of TXNIP protein and different clinical factors in pathological scar.The relative expression of TXNIP protein was 2.43±0.52 in the female group with pathological scars and 1.41±0.13 in the male group;2.11±0.68 in the age<40 years group and 1.72±0.36 in the age>40 years group;2.33±0.65 in the head and face group,2.07±0.66 in the trunk group and 1.74±0.55 in the extremities group;2.27±0.64 in the group with concomitant symptoms and 1.49±0.20 in the group without concomitant symptoms;2.21±0.65 in the group with treatment history,1.82±0.60 in the group without treatment history;2.42±0.24 in the group with family history,2.00±0.67 in the group without family history.The protein expression of TXNIP in pathological scars was significantly different among different groups of gender and concomitant symptoms(P<0.05),but there was no significant difference among different groups of age,location,treatment history and family history(P>0.05).Conclusion1.The expression levels of TXNIP in each group in descending order were keloid group,hypertrophic scar group,non-pathological scar group and normal skin group,suggesting that there may be a positive correlation between the severity of the scar and the expression level of TXNIP.2.Among all the variables studied,female and concomitant symptoms may be the most relevant clinical factors affecting TXNIP levels at the occurrence and development of pathological scar.